Clinical Trials on Stage IIB Non-Small Cell Lung Carcinoma in Italy

Total 700 results

GlaxoSmithKline
iTeos Therapeutics

Recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Lung Cancer, Non-Small Cell

Finland, Italy, Netherlands, Spain, United States, Argentina, Belgium, Brazil, Germany, Greece, Hungary, Korea, Republic of, United Kingdom, Poland, France, Thailand, Japan, South Africa, Turkey, United Arab Emirates, Mexico, Port...
Gruppo Oncologico Italia Meridionale

Unknown

Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer (ERACLE)

Non-squamous Nonsmall Cell Neoplasm of Lung

Italy
Istituto Clinico Humanitas

Completed

Role of FDG PET, Immune and Hypoxic Marker in NSCLC

Carcinoma, Non-Small-Cell Lung

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (Serpentine)

Melanoma | Renal Cell Carcinoma | Breast Cancer | NSCLC | Urinary Bladder Cancer | Squamous Cell Carcinoma of Head and Neck | Small Cell Carcinoma

Italy
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Non-Small Cell Lung Cancer

United States, Belgium, Hong Kong, Italy, Slovenia, Australia, Canada, Bulgaria, Germany, France, Georgia, Singapore, Spain, Bosnia and Herzegovina, Switzerland, Turkey, Japan, United Kingdom, Netherlands
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Lung Cancer

Spain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
Genentech, Inc.

Completed

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Non-Small Cell Lung Cancer

United States, Spain, Argentina, Israel, Hong Kong, Thailand, Australia, Belgium, Brazil, Bulgaria, Italy, Mexico, Philippines, Romania, Singapore, Taiwan, United Kingdom
Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, Netherlands, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Belgium, Lithuania, South Africa, Slovenia, Italy, ... and more
CNAO National Center of Oncological Hadrontherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Fondazione IRCCS... and other collaborators

Recruiting

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC)

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma

Italy, Germany
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Lithuania, South Africa, Slovenia, Italy, Canada, Belgium, Poland, Czech Republic and more
Hoffmann-La Roche

Active, not recruiting

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms, Nerve... and other conditions

Italy, Korea, Republic of, Australia, Spain, Argentina, Belgium, Brazil, France, Portugal, United Kingdom, United States, Japan, Mexico, Poland, Norway, Costa Rica, Switzerland, Netherlands, Germany, Sweden, Turkey, Ireland, Panama
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Non-Small Cell Lung Cancer

United States, Spain, United Kingdom, Japan, Turkey, Belgium, Germany, Netherlands, Canada, Singapore, Switzerland, Israel, Russian Federation, Korea, Republic of, Hong Kong, Lebanon, Italy, France, Portugal, Ireland
Boehringer Ingelheim

Completed

BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Carcinoma, Non-Small-Cell Lung

Italy
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
Gilead Sciences

Active, not recruiting

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

Non-Small Cell Lung Cancer

United States, Belgium, Spain, United Kingdom, Australia, Japan, Italy, France, Israel, Netherlands, Puerto Rico, Portugal, Greece, Brazil, Poland, Canada, Austria, Germany, Mexico, Turkey
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
GlaxoSmithKline

Active, not recruiting

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)

Lung Cancer, Non-Small Cell

Argentina, Korea, Republic of, Spain, Finland, Taiwan, Italy, Netherlands, Germany, Australia, Mexico, United States, Belgium, Canada, United Kingdom, Greece, Romania, Sweden, Russian Federation, Poland, France, Brazil, Japan, Thailand and more
Armando Santoro, MD

Terminated

Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

Small Cell Lung Cancer

Italy
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | T-Cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage...

United States, Denmark, Italy
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

Non-Small Cell Lung Cancer

United States, Italy, Poland, Spain, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Japan, Korea, Republic of, Lebanon, Mexico, Netherlands and more
Helsinn Healthcare SA

Completed

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Cachexia; Cancer

United States, Russian Federation, Bulgaria, Hungary, Italy, Romania, Serbia
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
European Organisation for Research and Treatment...
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Untreated Extensive SCLC (REACTION)

Small Cell Lung Cancer (SCLC)

United Kingdom, France, Italy
Fondazione Ricerca Traslazionale
Clinical research technology Srl

Active, not recruiting

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer (PFROST)

Carcinoma, Non-Small-Cell Lung

Italy
Hoffmann-La Roche

Active, not recruiting

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal)

Small Cell Lung Cancer | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Urothelial Carcinoma

Hungary, United Kingdom, Belgium, Croatia, France, Italy, Spain, United Arab Emirates, Argentina, Bulgaria, Poland, Philippines, Serbia, Netherlands, Romania, Colombia, Austria, Russian Federation, Singapore, Estonia, Egypt, India, ... and more
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
Takeda

Completed

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Spain, Italy, Netherlands, France
Amsterdam University Medical Centers (UMC), Location...
Mauna Kea Technologies

Recruiting

Confocal Laser Endomicroscopy VERification (CLEVER)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Lung Neoplasm Malignant | Neoplasm of Lung

United States, Austria, Greece, Netherlands, Czechia, Italy, Switzerland
Fondazione Ricerca Traslazionale

Unknown

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) (METROS)

Carcinoma, Non-Small-Cell Lung

Italy
Pfizer

Completed

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Italy
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation (TeRes)

Small Cell Lung Cancer Recurrent

Italy
Ariad Pharmaceuticals
Takeda

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

ALK-positive Advanced NSCLC

Korea, Republic of, United States, Spain, Taiwan, Canada, Hong Kong, China, Sweden, Australia, Italy, Japan, Germany, Netherlands, France, Austria
Pfizer

Completed

Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Italy
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
European Organisation for Research and Treatment...

Recruiting

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

Stage IB-IIB Cutaneous T-Cell Lymphoma

Spain, United Kingdom, Denmark, Italy, France, Germany, Greece
Takeda

Active, not recruiting

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

ALK+ Advanced NSCLC

Spain, China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Italy, Romania, United States, Mexico, Croatia, Russian Federation, Argentina, Canada, Germany, France, Austria, Chile, Greece, Sweden
Novartis Pharmaceuticals

Terminated

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, United States, Canada, France, Italy, Japan, Korea, Republic of, Spain
ETOP IBCSG Partners Foundation
Biodesix, Inc.

Completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (EMPHASIS)

Carcinoma, Non-Small-Cell Lung

Ireland, Switzerland, Denmark, Spain, United Kingdom, Belgium, Hungary, Greece, Israel, Austria, Italy, Netherlands
Incyte Corporation

Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Metastatic Melanoma | Unresectable Melanoma | Metastatic Urothelial Cancer | Metastatic Non-small Cell Lung Cancer | Locally Advanced Renal Cell Carcinoma | Locally Advanced Urothelial Cancer | Metastatic Clear-Cell Renal Cell Carcinoma

France, Spain, United States, Italy, Austria, Romania, Poland, Hungary
Gruppo Oncologico Italiano di Ricerca Clinica
YGHEA, CRO Division of Ecol Studio spa; Roche Pharma, Italy; Dr. Luca Boni U.O...

Active, not recruiting

Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE)

Small Cell Lung Cancer

Italy
Amgen

Completed

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Cancer | Lung Neoplasms | Non-Small Cell Lung Cancer | Thrombocytopenia | Lung Cancer | Solid Tumors | Oncology | Chemotherapy-Induced Thrombocytopenia

United States, Canada, Italy, Germany, Austria, Hungary, Portugal, Ireland
Boehringer Ingelheim

Completed

Real World Data on Gi(l)Otrif® Dose Adjustment

Carcinoma, Non-Small-Cell Lung

United States, Taiwan, Italy, Singapore, Austria, Canada, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Spain
National Cancer Institute, Naples

Active, not recruiting

STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study (STAD-1)

Small Cell Lung Cancer

Italy
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong

Clinical Trials on Stage IIB Non-Small Cell Lung Carcinoma in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations